Publications by authors named "G Evanno"
Island ecosystems, particularly vulnerable to environmental challenges, host many endangered native species. Diadromous fish, in particular, are threatened throughout their marine and freshwater habitats. The conservation of these species requires an in-depth understanding of their genetic diversity and structure, to better understand their adaptive potential.
View Article and Find Full Text PDFArticle Synopsis
- Recent research tested a new treatment called LIS1, derived from genetically modified pigs, to see if it could safely be used in kidney transplant patients instead of traditional rabbit-derived antithymocyte globulins (ATGs).
- The study showed that LIS1 effectively depleted T cells without causing major side effects, such as cytokine release syndrome, and was well tolerated by patients.
- Results indicated that LIS1 has a long half-life and allows for quick recovery of lymphocyte counts, suggesting it could be a promising alternative for transplant immunosuppression.
Article Synopsis
- XAV-19 is a targeted swine polyclonal antibody for SARS-CoV-2 that was tested for safety and effectiveness in patients with mild to moderate COVID-19 in a clinical trial.
- The trial was a phase II/III, double-blind, placebo-controlled study involving 279 patients where the primary focus was on whether XAV-19 could prevent disease worsening within eight days of treatment.
- Results indicated that while there were no significant differences in the primary endpoint, XAV-19 accelerated recovery times, particularly for patients with lower severity scores, and demonstrated effective neutralization against various COVID-19 variants.
Article Synopsis
- Polyclonal rabbit antithymocyte globulins (ATGs) used in organ transplants can cause unwanted inflammation, while LIS1, a new generation of antilymphocyte globulins derived from genetically modified pigs, aims to reduce these risks.
- A phase 1 study tested LIS1 in kidney transplant patients to assess its safety, T cell depletion effects, and pharmacokinetics.
- Results indicated that LIS1 was well tolerated, effectively depleted T cells in certain dosage groups, and did not provoke severe side effects or the formation of antidrug antibodies.
Article Synopsis
- The text indicates that the article with DOI: 10.3389/fimmu.2021.761250 has been corrected.
- Corrections are typically made to improve the accuracy of the published research.
- The specific details of the corrections are not included in the provided text.